FGF21 regulates circadian behavior and metabolism by acting on the nervous system

Angie L. Bookout1,2, Marleen H. M. de Groot3,4, Bryn M. Owen1, Syann Lee2, Laurent Gautron2, Heather L. Lawrence1, Xunshan Ding4, Joel K. Elmquist2, Joseph S. Takahashi3,4, David J. Mangelsdorf1,4,* and Steven A. Kliewer1,5,*

1Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas TX 75390, USA
2Department of Internal Medicine, Division of Hypothalamic Research, University of Texas Southwestern Medical Center, Dallas TX 75390, USA
3Department of Neuroscience, University of Texas Southwestern Medical Center, Dallas TX 75390, USA
4Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas TX 75390, USA
5Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas TX 75390, USA

Abstract

Fibroblast growth factor 21 (FGF21) is a hepatokine that acts as a global starvation signal to modulate fuel partitioning and metabolism, and repress growth1; however the site of action of these diverse effects remains unclear. FGF21 signals through a heteromeric cell surface receptor composed of one of three FGF receptors (FGFR1c, 2c, or 3c) in complex with β-Klotho2-4, a single-pass transmembrane protein that is enriched in metabolic tissues5. Here we show that in addition to its known effects on peripheral metabolism, FGF21 increases systemic glucocorticoid levels, suppresses physical activity, and alters circadian behavior, all features of the adaptive starvation response. These effects are mediated through β-Klotho expression in the suprachiasmatic nucleus (SCN) of the hypothalamus and the dorsal vagal complex (DVC) of the hindbrain. Mice lacking the β-Klotho gene (Klb) in these regions are refractory to these effects, as well as those on metabolism, insulin, and growth. These findings demonstrate a crucial role for the nervous system in mediating the diverse physiologic and pharmacologic actions of FGF21.
Previous studies showed that FGF21 can cross the blood-brain barrier, is detectable in human cerebrospinal fluid, and modulates phosphorylation cascades and gene expression in whole hypothalamus. Intracerebroventricular injection of FGF21 into rats increases metabolic rate and insulin sensitivity, although the site of action is unknown. To determine how and where FGF21 may be acting centrally, we first determined the expression of *Klb* in the nervous system using anatomically-guided laser capture microdissection (LCM) of specific hypothalamic and brainstem nuclei, and sensory ganglia from parasympathetic and sympathetic divisions of the peripheral nervous system. Quantitative PCR (QPCR) showed that *Klb* is selectively expressed in the hypothalamus in the SCN (Fig. 1a), the site of a circadian pacemaker that orchestrates entrainment of animals to their external environment and gates the timing of diverse behavioral, physiological, and hormonal rhythms. We found that *Klb* is also expressed in the hindbrain in key sets of neurons of the DVC, including the area postrema (AP) and the nucleus tractus solitarii (NTS), and in the nodose ganglia, where vagal nerve sensory neurons reside (Fig. 1a). The components of the vagus nerve and its targets in the brainstem comprise a sensory unit that receives and integrates information from the viscera regarding metabolic and physiologic status. The localization of *Klb* in the SCN and DVC was confirmed by in situ hybridization (Fig. 1b; Supplementary Fig. 1). In contrast to *Klb*, *Fgfr1c*, *Fgfr2c*, and *Fgfr3c* are broadly expressed in the nervous system (Fig. 1a). *Fgf21* mRNA is undetectable in any of these regions (data not shown).

Since *Klb* localized to the SCN, we evaluated the circadian effect of long-term FGF21 exposure on gene expression and metabolic parameters using Tg(Fgf21) mice, in which an *Fgf21* transgene is under the control of the liver-selective apolipoprotein E promoter. Plasma FGF21 levels varied between 1000 and 2000 ng ml⁻¹ in Tg(Fgf21) mice (Supplementary Fig. 2a). In hypothalamus, the circadian pattern of *Klb* expression was unchanged in Tg(Fgf21) mice (Supplementary Fig. 2b). There also was no change in the expression of *Fgfr1c* or the circadian genes, *Bmal1*, *Clock* and *Per2*, in the hypothalamus of Tg(Fgf21) mice (Supplementary Fig. 2b). In liver, *Klb* was consistently higher in the Tg(Fgf21) compared to wild-type mice (Supplementary Fig. 2c). There were modest changes in the expression of the clock genes *Bmal1*, *Clock* and *Per2* in liver, which are likely a consequence of changes in SCN output and corticosterone levels (see below). Liver expression of insulin-like growth factor binding protein-1 (*Igfbp1*), cytochrome P450 (*Cyp2d9*) and hydroxysteroid dehydrogenase (*Hsd3b5*), which are regulated by growth hormone, was reciprocally regulated in Tg(Fgf21) mice throughout the cycle (Supplementary Fig. 2c). Plasma insulin, glucose, triglyceride and cholesterol concentrations were consistently lower in Tg(Fgf21) mice throughout the light cycle (Supplementary Fig. 2a). Taken together, these data indicate that FGF21 does not affect central clock genes but might affect SCN output.

To test directly whether the SCN is a target of FGF21 action, we deleted the *Klb* gene from the SCN by crossing *Klb*tm1(Camk2a) mice with a calcium/calmodulin-dependent protein kinase IIa (Camk2a)-Cre line in which cre recombinase is expressed widely in the forebrain and hindbrain. In the resulting *Klb*tm1(Camk2a) mice, *Klb* mRNA expression was reduced in both the SCN and DVC to 15% of wild-type levels by 6 months of age (Fig. 1c). *Klb* expression was unaffected in liver and adipose tissue (Supplementary Fig. 3a). To control for deletion of *Klb* in the DVC, we crossed *Klb*tm1 mice with a Phox2b-Cre line that...
is expressed in the hindbrain\(^1\), including neurons in the dorsal motor nucleus of the vagus, NTS, AP, and nodose ganglia. In the resulting \(Klb^{tm1(Phox2b)}\) mice, \(Klb\) expression was lower in the DVC but not in the SCN, liver or adipose tissues compared to \(Klb^{tm1}\) controls (Fig. 1c; Supplementary Fig. 3b).

To study the effects of FGF21 on the nervous system, \(Klb^{tm1(Camk2a)}\) or \(Klb^{tm1(Phox2b)}\) mice were bred to the Tg(Fgf21) mice. Plasma FGF21 concentrations were elevated to similar levels in all Tg(Fgf21) mouse lines (Supplementary Table 1). Since the primary function of the SCN is to drive circadian behavior and to entrain these rhythms to light cycles, we measured the effect of FGF21 overexpression on daily wheel-running behavior under various lighting conditions. Representative actograms for wild-type and Tg(Fgf21) mice are shown (Fig. 2a, 2b, and Supplementary Fig. 4a). Tg(Fgf21) mice exhibited significantly lower total wheel-running activity compared to wild-type mice (Fig. 2c, 2d; Supplementary Table 2), resulting in lower amplitude rhythms as assessed by fast Fourier transform (FFT) analysis (Supplementary Table 2). Additionally, the Tg(Fgf21) mice failed to consolidate their running to the dark phase (Fig. 2c, 2d; Supplementary Table 2). Overall, activity remained nocturnal in both wild-type and Tg(Fgf21) mice (Fig. 2c; Supplementary Table 2), demonstrating that entrainment to light was intact, although the phase angle of entrainment was advanced for the Tg(Fgf21) mice. To determine whether the pace of the circadian clock was affected, we measured the free-running period length of the activity rhythm in constant darkness. The circadian period for all mice was identical (23.5 ± 0.1 hours; Supplementary Table 2), demonstrating that the behavioral alterations seen in the Tg(Fgf21) mice are likely due to an inhibition of clock output rather than an effect on the molecular clock \(\text{per se}\).

To assess whether the behavioral alterations observed for Tg(Fgf21) mice were mediated by the SCN, we evaluated \(Klb^{tm1;\text{Tg(Fgf21)}}\) and \(Klb^{tm1(Camk2a);\text{Tg(Fgf21)}}\) mice on running wheels. Compared to wild-type mice and similar to Tg(Fgf21) mice, \(Klb^{tm1;\text{Tg(Fgf21)}}\) animals exhibited lower overall activity, reduced robustness of rhythm, and higher running during the light phase (Fig. 2e, 2h; Supplementary Fig. 4b; Supplementary Table 2). Deletion of \(\beta\)-Klotho in the nervous system normalized these parameters (Fig. 2f, 2g, 2h; Supplementary Fig. 4b; Supplementary Table 2) demonstrating the importance of the SCN in mediating these behaviors in response to chronically elevated FGF21. These data provide further evidence that elevated FGF21 relaxes the inhibitory function of the SCN on activity during the light phase.

To test whether endogenous FGF21 regulates circadian behaviors, we performed wheel-running experiments with wild-type and \(Fgf21^{-/-}\) mice fed a ketogenic diet. Although it was not technically possible to administer FGF21 to mice while they are in the wheel-running experiments, the ketogenic diet offers an alternative method by mimicking the starvation response and increasing \(Fgf21\) mRNA in liver and FGF21 concentrations in blood to near fasting levels (ref. \(^2\); Supplementary Fig. 5a). In our experiments, the ketogenic diet increased plasma FGF21 levels to 10–30 ng ml\(^{-1}\) (Supplementary Fig. 5a; Supplementary Table 3). When challenged with the ketogenic diet, wild-type mice reduced overall activity while increasing activity during the light phase (Fig. 3a–c, 3g, 3h; Supplementary Fig. 5b; Supplementary Table 3), similar to that seen in Tg(Fgf21) mice (Fig. 2c). Chow-fed \(Fgf21^{-/-}\) mice behaved like their wild-type counterparts (Fig. 3d). While total activity was

*Nat Med.* Author manuscript; available in PMC 2014 March 01.
similarly lower in wild-type and Fgf21−/− mice in response to the ketogenic diet (Fig. 3e–g; Supplementary Table 3), the diet-induced increase in light phase activity was significantly attenuated in Fgf21−/− mice (Fig. 3h; Supplementary Table 3; Supplementary Fig. 5b). Thus, physiologic levels of FGF21 can modulate circadian behavior.

We next evaluated the consequence of eliminating β-Klotho from the nervous system on metabolic parameters. Neither the Klb<sup>tm1(Camk2a)</sup> or Klb<sup>tm1(Phox2b)</sup> mice had changes in body weight or other metabolic parameters under ad libitum chow-fed conditions (Fig 4a; Supplementary Table 1). As expected<sup>16,21</sup>, Klb<sup>tm1: Tg(Fgf21)</sup> mice had significantly lower body weight, tibia length and plasma insulin and cholesterol concentrations than control Klb<sup>tm1</sup> mice but no change in percent lean mass or fat mass (Fig. 4a; Supplementary Fig. 6a; Supplementary Table 1). Notably, the changes in body weight, tibia length and plasma insulin and cholesterol concentrations observed in Klb<sup>tm1: Tg(Fgf21)</sup> mice were reversed in Klb<sup>tm1(Camk2a): Tg(Fgf21)</sup> mice (Fig. 4a; Supplementary Fig. 6a; Supplementary Table 1). These changes were not reversed in Klb<sup>tm1(Phox2b): Tg(Fgf21)</sup> mice with the exception of cholesterol concentrations (Fig. 4a; Supplementary Table 1). These data indicate that FGF21 action on the SCN mediates the effects of FGF21 on body weight and insulin levels.

Since glucocorticoids play a crucial role in the starvation response and are regulated by both the SCN and hindbrain<sup>22,23</sup>, we examined glucocorticoid homeostasis in Tg(Fgf21) mice. Consistent with lowered SCN clock output, arginine vasopressin (Avp) expression was lower and corticotropin releasing hormone (Crh) expression was higher in hypothalamus of Tg(Fgf21) mice compared to wild-type mice (Supplementary Fig. 2b). These changes were accompanied by higher concentrations of plasma corticosterone and lower concentrations of adrenocorticotropic hormone (ACTH) (Supplementary Fig. 2a). In Klb<sup>tm1: Tg(Fgf21)</sup> mice, plasma corticosterone was ~4-fold higher compared to control Klb<sup>tm1</sup> mice, and this effect was lost in Klb<sup>tm1(Camk2a): Tg(Fgf21)</sup> mice (Fig. 4b). Plasma ACTH concentrations were regulated in a reciprocal manner (Fig. 4b), indicating that feedback regulation at the level of the pituitary is intact in the Klb<sup>tm1: Tg(Fgf21)</sup> mice. A similar pattern of corticosterone and ACTH regulation was seen in experiments performed with Klb<sup>tm1(Phox2b): Tg(Fgf21)</sup> mice, although the plasma corticosterone in Klb<sup>tm1: Tg(Fgf21)</sup> mice did not reach statistically higher levels relative to Klb<sup>tm1</sup> control mice in these experiments (Fig. 4b). Together, these data indicate that FGF21 acts on both the SCN and hindbrain regions of the nervous system to increase corticosterone levels.

We next assessed the consequences of eliminating β-Klotho from the SCN on FGF21-regulated gene expression in liver and adipose tissue. In liver, Klb<sup>tm1: Tg(Fgf21)</sup> mice had higher Igfbp1 mRNA levels, and lower Cyp2d9 and Hsd3b5 mRNA levels compared to Klb<sup>tm1</sup> control mice (Fig. 4c). The effect of the Fgf21 transgene on the expression of these genes was lost in Klb<sup>tm1(Camk2a): Tg(Fgf21)</sup> mice but not in Klb<sup>tm1(Phox2b): Tg(Fgf21)</sup> mice (Fig. 4c), which is consistent with FGF21 acting on the SCN to regulate growth. Hepatic expression of the gluconeogenic gene, phosphoenolpyruvate carboxykinase (Pck1), which is induced by glucocorticoids, was higher in Klb<sup>tm1: Tg(Fgf21)</sup> mice compared to those without Tg(Fgf21) (Fig. 4d). Consistent with the FGF21-dependent CNS effects on plasma corticosterone, Pck1 expression was unchanged in Klb<sup>tm1(Camk2a): Tg(Fgf21)</sup> mice and trended lower in Klb<sup>tm1(Phox2b): Tg(Fgf21)</sup> mice (Fig. 4d). In adipose tissue, adipose
triglyceride lipase (Atgl), stearoyl-Coenzyme A desaturase 1 (Scd1), and hydroxysteroid dehydrogenase 11b1 (Hsd11b1) were higher in Klb<sup>tm1</sup>:Tg(Fgf21) mice compared to Klb<sup>tm1</sup> control mice (Supplementary Fig. 6b). The FGF21-dependent expression of these genes was unaffected in both the Klb<sup>tm1(Camk2a)</sup>:Tg(Fgf21) and Klb<sup>tm1(Phox2b)</sup>:Tg(Fgf21) mice (Supplementary Fig. 6b), consistent with the notion that FGF21 acts directly on white adipose tissue to regulate their expression<sup>17</sup>. Finally, given the pharmacologic levels of circulating FGF21 in the Tg(Fgf21) mice, we performed an experiment in which physiologic levels of FGF21 were delivered by mini-pump for 7 days to Klb<sup>tm1</sup> and Klb<sup>tm1(Camk2a)</sup> mice. Under these conditions, steady-state plasma FGF21 concentrations were ~9 ng ml<sup>-1</sup> (Fig. 4e), which is comparable to peak levels obtained during starvation (ref. 19; Supplementary Fig. 6c) and lower than those obtained by ketogenic diet feeding (ref. 20; Supplementary Fig. 5a). There was no effect of FGF21 administration on body weight (Fig. 4f). In agreement with the Tg(Fgf21) studies, FGF21 reduced basal plasma insulin concentrations in Klb<sup>tm1</sup> but not Klb<sup>tm1(Camk2a)</sup> mice (Fig. 4f). Importantly, FGF21 significantly increased plasma corticosterone levels in Klb<sup>tm1</sup> but not Klb<sup>tm1(Camk2a)</sup> mice (Fig. 4g). In gene expression studies, FGF21 increased Igbp1 and Pck1 expression and decreased Cyp2d6 and Hsd3b5 expression in livers of Klb<sup>tm1</sup> but not Klb<sup>tm1(Camk2a)</sup> mice (Fig. 4h, 4i). These data recapitulate those seen in the Tg(Fgf21) studies and demonstrate that physiologic concentrations of FGF21 act on the nervous system to regulate metabolism.

In summary, we show that FGF21 acts directly through its co-receptor β-Klotho in the brain to lower insulin, inhibit growth, and alter light/dark cycle activity, all of which occur during starvation<sup>24,25</sup>. Coincident with this role, we show that FGF21 acts on the nervous system, both at the level of the hypothalamus and the hindbrain, to increase systemic corticosterone levels, another prominent feature of starvation. This latter finding may explain the liver nonautonomous inductive effect of FGF21 on hepatic gluconeogenesis<sup>26</sup>. In an accompanying paper (Owen<sup>et al.</sup>), we show that FGF21 also acts as a starvation signal to inhibit female fertility. These effects on circadian behavior, glucocorticoids, metabolism, and reproduction are consistent with our results showing that FGF21 suppresses the expression of the neuropeptide vasopressin in the SCN (Supplementary Fig. 2b; Owen<sup>et al.</sup>). The finding that diverse effects of FGF21 are mediated by suppressing the output of the SCN (and by acting on the DVC) reveals a previously unrecognized regulatory circuit between the liver and brain. Although not typically regarded as being influenced by diet, the SCN expresses receptors for other metabolic factors, including leptin and ghrelin<sup>27,28</sup>. Thus, the SCN appears to play a broad role in gating adaptive responses to nutritional status. Finally, the observation that, in addition to starvation, FGF21 is elevated in conditions related to the metabolic syndrome<sup>29</sup> raises the possibility that FGF21 working through the nervous system may play a part in mediating some of the established effects of the metabolic syndrome on circadian and metabolic parameters.
Online Methods

Animals

All procedures and use of animals were approved by the Institutional Animal Care and Use Committee of UT Southwestern Medical Center Dallas. Unless otherwise stated in specific dietary studies, all animals were maintained on 2916 Global Diet (Harlan Teklad). Ketogenic diet was from BioServ F3666. Male mice were used in all studies. C57BL/6J mice used for LCM and in situ hybridization were obtained from Jackson or from the UT Southwestern mouse breeding core, which sources its colony breeders from Jackson. The C57BL/6J Tg(Fgf21), C57BL/6J Fgf21−/−, C57BL/6J;129/Sv Klb tm1, and C57BL/6J Camk2a-cre lines have been previously described16-18,26. The C57BL/6J Phox2b-cre line 4 expresses cre recombinase in the hindbrain to a greater extent than line 3, in addition to some hypothalamic (excluding the SCN) and cortical sites19. Animals were sacrificed at times indicated by rapid decapitation to avoid stress responses. Trunk blood was collected into K+EDTA tubes, and plasma was separated and stored at −80 °C until assayed. Tissues were collected, snap-frozen in liquid nitrogen, and stored at −80 °C until assayed. For minipump experiments, Alzet micro-osmotic pumps model 1007D were filled with vehicle (25 mM HEPES, 150 mM NaCl, 50% glycerol) or recombinant human FGF21 (to deliver 1.1 μg in 0.5 μl per hour) and implanted subcutaneously under isofluorane inhalation anaesthesia. Animals were sacrificed by decapitation at ZT3, 7-days after implantation.

Neuroanatomical Mapping

Laser Capture Microdissection and Peripheral Ganglia—At the start of the light cycle, C57BL/6J males were deeply anesthetized with chloral hydrate and decapitated. Left nodose ganglion and mid-thoracic dorsal root ganglia were rapidly collected and frozen in liquid nitrogen. Brains were dissected, slow-frozen on dry ice, and stored at −80 °C until sectioning. Brains were cryosectioned at 30 μm and thaw-mounted onto silanecoated PEN membrane glass slides (Molecular Devices, Sunnyvale, CA) and stored at −80 °C. Slides were lightly fixed in 75% ethanol immediately prior to thionin staining. Slides were then dehydrated in a graded ethanol series followed by 5 minutes in xylenes. The Arcturus Veritas Microdissection System (Molecular Devices) was used to isolate each nucleus based on defined neuroanatomical boundaries30 as described previously31. Nuclei collected are listed in Supplementary Table 4.

Peripheral ganglia RNA was isolated using Ambion’s Ribopure kit, while LCM nuclei RNA was extracted using the PicoPure RNA Isolation Kit (Molecular Devices) with on-column DNAsel treatment (Qiagen, Valencia, CA), and stored at −80 °C. RNA quality was assessed using the Experion Automated Electrophoresis system (Bio-Rad, Hercules, CA).

cDNA was synthesized using the High Capacity cDNA Kit (Applied Biosystems), followed by cDNA pre-amplification of specific gene targets using TaqMan Preamplification Buffer (Applied Biosystems), according to the manufacturer’s directions. Due to sufficiently high expression, it was not necessary to pre-amplify 18S rRNA, which was used as the normalizer gene. All gene expression levels were measured with an Applied Biosystems 7900HT Sequence Detection System using the efficiency-corrected ΔCt method as
The anatomic specificity of the LCM dissections was confirmed by QPCR for the expression of known marker genes in each nucleus.

**In situ hybridization**—C57BL/6J males were deeply anesthetized with chloral hydrate and transcardially perfused with saline, followed by formalin. Brains were dissected and post-fixed in formalin for several hours prior to overnight incubation in 20% sucrose. Brains were cut at 25 μm, 1:4 series using a sliding microtome, and sections stored in cryoprotectant at −20 °C until use. Free-floating *in situ* hybridization was carried out as described using a 33P-labelled anti-sense probe for *Klb* cDNA (spanning base pairs 169–692). Sections were mounted onto SuperFrost plus slides, rostral to caudal and exposed to film for approximately 4 days. Developed film was scanned using an Epson ImageScanner III.

**Quantitative Real Time PCR**

Total RNA from liver, white, and brown adipose was isolated using RNA Stat60 (Teltest), and cDNA was synthesized using the High Capacity cDNA Kit (Applied Biosystems). Gene expression profiles of peripheral tissues were performed using the ΔΔCt assay as described.

**Blood Analyses**

Glucose, ketones, cholesterol, and triglycerides were measured by colorimetric assays (Wako, Pointe Scientific); corticosterone and ACTH by radioimmunoassay (MP Biomedical); insulin and mouse or human FGF21 by ELISA (Crystal Chem, Biovendor), according to manufacturers’ instructions.

**Wheel-Running**

Wheel-running experiments were performed as described. Singly-housed animals were entrained to a 12 hour light, 12 hour dark cycle (LD12:12) for 18 days, followed by 21 days of constant darkness (DD), before return to LD12:12 for 15 days. Data were analyzed using ClockLab. Total daily activity, % light, and % dark counts were taken from days 6–15 of LD recording. Period and amplitude were calculated from days 29 to 38 during DD. Phase was determined using activity onsets on days 22 to 28 with extrapolation to the first day of DD (day 19).

**Statistics**

Data are presented as mean ± SEM. GraphPad Prism was used for ANOVA with Bonferroni’s post-hoc test or two-tailed Student’s *t*-test. *P* < 0.05 was considered significant.

**Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.

**Acknowledgments**

We thank Y. Zhang, K. Vale, and E. Borowicz for help with animal studies; X. Wang and Y. Wan for tibia measurements; D. Lauzon and C. Lee for *in situ* hybridization; M. Izumo for *Camk2a*-cre mice; M. Scott for...
Phox2b-cre mice; C. Cummins for advice on glucocorticoid and ACTH assays; and all members of the Takahashi, Elmquist, and Mango/Kliewer laboratories for critical discussions. This work was supported by US National Institutes of Health grants DK067158, P20RR20691, and 1RL1GM084436-01 (to S.A.K. and D.J.M.), U19DK62434 (to J.K.E. and D.J.M.), P01DK088761, R1IDKO81185 (to J.K.E.), and GM007062 (to A.L.B.); the Robert A. Welch Foundation (grant I-1558 to S.A.K., grant I-1275 to D.J.M.); and the Howard Hughes Medical Institute (to J.S.T. and D.J.M.).

References

1. Potthoff MJ, Kliewer SA, Mangelsdorf DJ. Endocrine fibroblast growth factors 15/19 and 21: from feast to famine. Genes Dev. 2012; 26:312–324. [PubMed: 22302876]
2. Kharitonenkov A, et al. FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho. Journal of cellular physiology. 2008; 215:1–7. [PubMed: 18064602]
3. Ogawa Y, et al. BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104:7432–7437. [PubMed: 17452648]
4. Suzuki M, et al. betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol Endocrinol. 2008; 22:1006–1014. [PubMed: 18187602]
5. Fon Tacer K, et al. Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol. 2010; 24:2050–2064. [PubMed: 20667984]
6. Hscouchou H, Pan W, Kastin AJ. The fasting polypeptide FGF21 can enter brain from blood. Peptides. 2007; 28:2382–2386. [PubMed: 17996984]
7. Tan BK, et al. Fibroblast growth factor 21 (FGF21) in human cerebrospinal fluid: relationship with plasma FGF21 and body adiposity. Diabetes. 2011; 60:2758–2762. [PubMed: 21926274]
8. Yang C, et al. Differential Specificity of Endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in Complex with KLB. PloS one. 2012; 7:e33870. [PubMed: 22442730]
9. Coskun T, et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology. 2008; 149:6018–6027. [PubMed: 18687777]
10. Sarruf DA, et al. Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats. Diabetes. 2010; 59:1817–1824. [PubMed: 20357365]
11. Dibner C, Schibler U, Albrecht U. The mammalian circadian timing system: organization and coordination of central and peripheral clocks. Annual review of physiology. 2010; 72:517–549.
12. Huang W, Ramsey KM, Marcheva B, Bass J. Circadian rhythms, sleep, and metabolism. The Journal of clinical investigation. 2011; 121:2133–2141. [PubMed: 21633182]
13. Buijs RM, Kalsbeek A. Hypothalamic integration of central and peripheral clocks. Nature reviews. Neuroscience. 2001; 2:521–526. [PubMed: 11433377]
14. Welsh DK, Takahashi JS, Kay SA. Suprachiasmatic nucleus: cell autonomy and network properties. Annual review of physiology. 2010; 72:551–577.
15. Lowey, AD.; Spyer, M. Central Regulation of Autonomic Functions. Oxford University Press; USA: 1990.
16. Inagaki T, et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell metabolism. 2007; 5:415–425. [PubMed: 17507777]
17. Ding X, et al. betaKlotho Is Required for Fibroblast Growth Factor 21 Effects on Growth and Metabolism. Cell metabolism. 2012; 16:387–393. [PubMed: 22958921]
18. Casanova E, et al. A CamKIIalpha iCre BAC allows brain-specific gene inactivation. Genesis. 2001; 31:37–42. [PubMed: 11686876]
19. Scott MM, Williams KW, Rossi J, Lee CE, Elmquist JK. Leptin receptor expression in hindbrain Glp-1 neurons regulates food intake and energy balance in mice. The Journal of clinical investigation. 2011; 121:2413–2421. [PubMed: 21606595]
20. Badman MK, Koester A, Flier JS, Kharitonenkov A, Maratos-Flier E. Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology. 2009; 150:4931–4940. [PubMed: 19819944]
21. Inagaki T, et al. Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. Cell metabolism. 2008; 8:77–83. [PubMed: 18585098]
22. Buijs RM, Kalsbeek A, van der Woude TP, van Heerikhuize JJ, Shinn S. Suprachiasmatic nucleus lesion increases corticosterone secretion. The American journal of physiology. 1993; 264:R1186–1192. [PubMed: 8322972]

23. Ritter S, Dinh TT, Zhang Y. Localization of hindbrain glucoreceptive sites controlling food intake and blood glucose. Brain research. 2000; 856:37–47. [PubMed: 10677609]

24. Cahill GF Jr. Fuel metabolism in starvation. Annual review of nutrition. 2006; 26:1–22.

25. Wang T, Hung CC, Randall DJ. The comparative physiology of food deprivation: from feast to famine. Annual review of physiology. 2006; 68:223–251.

26. Potthoff MJ, et al. FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106:10853–10858. [PubMed: 19541642]

27. Hakansson ML, Brown H, Ghilardi N, Skoda RC, Meister B. Leptin receptor immunoreactivity in chemically defined target neurons of the hypothalamus. The Journal of neuroscience : the official journal of the Society for Neuroscience. 1998; 18:559–572. [PubMed: 9412531]

28. Zigman JM, Jones JE, Lee CE, Saper CB, Elmquist JK. Expression of ghrelin receptor mRNA in the rat and the mouse brain. The Journal of comparative neurology. 2006; 494:528–548. [PubMed: 16320257]

29. Woo YC, Xu A, Wang Y, Lam KSL. Fibroblast Growth Factor 21 as an emerging metabolic regulator: clinical perspectives. Clinical endocrinology. 2013; 78:489–496. [PubMed: 23134073]

30. Paxinos, G.; Franklin, KBJ. The Mouse Brain in Stereotaxic Coordinates. Academic Press; San Diego, CA: 2003.

31. Lee S, et al. Laser-capture microdissection and transcriptional profiling of the dorsomedial nucleus of the hypothalamus. The Journal of comparative neurology. 2012

32. Bookout, AL.; Cummins, CL.; Mangelsdorf, DJ.; Pesola, JM.; Kramer, MF. High-throughput real-time quantitative reverse transcription PCR. In: Ausubel, Frederick M., et al., editors. Current protocols in molecular biology. Vol. Chapter 15. 2006. p. 18

33. Cummins CL, et al. Liver X receptors regulate adrenal cholesterol balance. The Journal of clinical investigation. 2006; 116:1902–1912. [PubMed: 16823488]

34. Siepka SM, Takahashi JS. Methods to record circadian rhythm wheel running activity in mice. Methods in enzymology. 2005; 393:230–239. [PubMed: 15817291]

35. Shimomura K, et al. Genome-wide epistatic interaction analysis reveals complex genetic determinants of circadian behavior in mice. Genome research. 2001; 11:959–980. [PubMed: 11381025]
Figure 1.
Klb and Fgfr expression in the nervous system. (a) LCM mRNA expression in nonhypothalamic (CTX, Thal AD), hypothalamic (OVLT to PMV), midbrain (VTA to mPBN), hindbrain (AP to NTS), and peripheral nervous system (nodose, DRG) regions of male C57BL/6J mice (n = 4–5) harvested at the start of the light phase (see Supplementary Table 4 for abbreviations). (b) In situ hybridization of Klb from hypothalamus (top) and hindbrain (bottom) coronal sections (see Supplementary Fig. 1 for full panel of coronal sections; bar = 45 mm). (c) Klb expression in blunt-dissected SCN and DVC from Klb<sup>tm1(Camk2a)</sup> and Klb<sup>tm1(Phox2b)</sup> mice. Cycle time (Ct) values shown inside bars. Data represent the mean ± SEM. Asterisks indicate significant differences (P < 0.05) relative to – cre controls.
Figure 2.
Transgenic overexpression of FGF21 alters wheel-running behavior through the SCN. Representative actograms are shown double-plotted for (a) wild-type (WT), (b) Tg(Fgf21), (e) Klb tm1∷Tg(Fgf21), and (f) Klb tm1(Camk2a)∷Tg(Fgf21) males. Yellow indicates light phase (LD, 12 hours light/12 hours dark; DD, constant darkness). (c, g) Average wave plots summarize wheel-running activity during days 6–15 of LD for indicated genotypes (n = 16–28). Time on x-axis refers to zeitgeber time (ZT) 0 at lights on. (d, h) Daily total and % light phase wheel-running activity for the indicated genotypes are plotted as mean ± SEM (*P < 0.05).
Figure 3.
Endogenous FGF21 alters wheel-running behavior. Representative actograms are shown double-plotted for wild-type (WT) (a, b) and Fgf21<sup>−/−</sup> (d, e) males on standard chow (a, d) or ketogenic (b, e) diets. Yellow indicates light phase (LD, 12 hours light/12 hours dark; DD, constant darkness). (c, f) Average wave plots summarize wheel-running activity during days 6–15 of LD for indicated genotypes (n = 6–24). Time on x-axis refers to ZT0 at lights on. (g, h) Daily total and % light phase wheel-running activity for the indicated genotypes are plotted as mean ± SEM. Asterisks indicate significant differences (P < 0.05) compared to chow diets in (g) and as indicated in (h).
**Figure 4.**

*Klb* expression in the SCN is required for FGF21 suppression of growth and insulin, and stimulation of glucocorticoid activity. (a – d) Male mice of indicated genotypes without (−) or with (Tg21) the Tg(Fgf21). (e – i) Male mice of indicated genotypes implanted with osmotic mini-pumps delivering vehicle (V) or human FGF21. Animals were sacrificed at ZT8 (a, c), ZT3 (e – i), or at ZT0 (b, d), and body weight, plasma hormone levels, and liver gene expression were determined. Data represent mean ± SEM, n = 5–9 for (a – d) and n = 6 for (e – i). Ct values shown inside bars. Asterisks indicate significant differences (*P* < 0.05) compared to (−) or (V) controls, or as indicated.